No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease.
Smadja
David M
DM
Loriot
Marie-Anne
MA
Hindorff
Lucia A
LA
Mellottee
Lucille
L
Gaussem
Pascale
P
Emmerich
Joseph
J
D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D016022:Case-Control Studies; D004351:Drug Resistance; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006239:Haplotypes; D006801:Humans; D008297:Male; D006899:Mixed Function Oxygenases / Q000235:genetics*; D016017:Odds Ratio; D016491:Peripheral Vascular Diseases / Q000188:drug therapy / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D018570:Risk Assessment; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000188:drug therapy / Q000235:genetics*; D020246:Venous Thrombosis / Q000188:drug therapy / Q000235:genetics*; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases